Celcuity (CELC)
(Delayed Data from NSDQ)
$15.19 USD
+0.18 (1.20%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $15.19 0.00 (0.00%) 6:20 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$15.19 USD
+0.18 (1.20%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $15.19 0.00 (0.00%) 6:20 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Zacks News
Can Celcuity (CELC) Climb 87.59% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at an 87.6% upside potential for Celcuity (CELC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Celcuity (CELC) Upgraded to Buy: Here's Why
by Zacks Equity Research
Celcuity (CELC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Why Celcuity (CELC) Might Surprise This Earnings Season
by Zacks Equity Research
Celcuity (CELC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Wall Street Analysts Think Celcuity, Inc. (CELC) Could Surge 359%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Celcuity, Inc. (CELC) points to a 359.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Can Celcuity, Inc. (CELC) Climb 462% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 461.9% in Celcuity, Inc. (CELC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Celcuity, Inc. (CELC) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
Celcuity, Inc. (CELC) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Celcuity's (CELC) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Celcuity Inc. (CELC).
Company News for Apr 12, 2021
by Zacks Equity Research
Companies in the news are: AFMD, FUBO, GENE, CELC
Celcuity (CELC) Soars on Agreement With Pfizer & Study Data
by Zacks Equity Research
Celcuity (CELC) is developing gedatolisib in combination with Pfizer's Ibrance and an endocrine therapy in breast cancer patients. It inks deal to gain exclusive rights to gedatolisib from Pfizer.
Company News for Mar 18, 2021
by Zacks Equity Research
Companies in the news are: LE, SMTC, CRAWA, CELC
The Zacks Analyst Blog Highlights: Red Robin, Celcuity, Atlas Air and Boston Private
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Red Robin, Celcuity, Atlas Air and Boston Private
4 Small Cap Stocks to Get Rid of Before Entering 2020
by Nikita Kataruka
While domestic economic growth has been benefiting small-cap stocks until now, you should consider selling some of the stocks before entering 2020 because of poor earnings growth projections.
All You Need to Know About Celcuity, Inc. (CELC) Rating Upgrade to Buy
by Zacks Equity Research
Celcuity, Inc. (CELC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Paratek Pharmaceuticals (PRTK) Catches Eye: Stock Jumps 10.2%
by Zacks Equity Research
Paratek Pharmaceuticals (PRTK) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
Ultragenyx to Submit sBLA for Label Expansion of Crysvita
by Zacks Equity Research
Ultragenyx (RARE) and partner Kyowa Kirin plan to submit an sBLA to the FDA for the label expansion of Crysvita.
Adaptimmune (ADAP) Gets Orphan Drug Status for T-cell Therapy
by Zacks Equity Research
Adaptimmune Therapeutics (ADAP) gets Orphan Drug Designation for SPEAR T-cells targeting MAGE-A4 (ADP-A2M4 program) for the treatment of soft tissue sarcomas.
Horizon's (HZNP) Eye Disease Drug Gets FDA's Priority Review
by Zacks Equity Research
Horizon (HZNP) announces the FDA has accepted the Biologics License Application (BLA) for teprotumumab, for the treatment of active thyroid eye disease, and granted it Priority Review designation.
Nabriva (NBRV) Aims to Resubmit Contepo NDA in Q4
by Zacks Equity Research
Nabriva (NBRV) intends to resubmit the NDA for Contepo in Q4. The intravenous candidate is being studied for treating patients with complicated urinary tract infection including acute pyelonephritis.
Celcuity, Inc. (CELC) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Celcuity, Inc. (CELC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
What Makes Celcuity, Inc. (CELC) a New Strong Buy Stock
by Zacks Equity Research
Celcuity, Inc. (CELC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Celcuity, Inc. (CELC) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Celcuity, Inc. (CELC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Autolus Therapeutics (AUTL) Catches Eye: Stock Jumps 5.6%
by Zacks Equity Research
Autolus Therapeutics (AUTL) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
InflaRx (IFRX) Catches Eye: Stock Jumps 7.5%
by Zacks Equity Research
InflaRx (IFRX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Nabriva Therapeutics (NBRV) in Focus: Stock Moves 7.5% Higher
by Zacks Equity Research
Nabriva Therapeutics (NBRV) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Krystal (KRYS) in Focus: Stock Moves 5.1% Higher
by Zacks Equity Research
Krystal (KRYS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.